BindingDB Entry 50036796: Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.

Name: BindingDB Entry 50036796: Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.
Creator: BindingDB
Keywords: Phosphodiesterase 1, Phosphodiesterase 3, Phosphodiesterase 4, cGMP-dependent 3',5'-cyclic phosphodiesterase, and cGMP-specific 3',5'-cyclic phosphodiesterase, Tanabe Seiyaku Company, Ltd., Affinity, 3. Good health

Research datakeyboard_double_arrow_right Dataset 01 Jan 2012 English Publisher:BindingDB

Authors: BindingDB;

doi: 10.7270/q25m66dh

BindingDB Entry 50036796: Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.

- Summary
- Subjects
- Related research
  (13)
- Metrics

tips_and_updates
Recommended

Abstract

Small molecule binding data for protein Phosphodiesterase 1, Phosphodiesterase 3, Phosphodiesterase 4, cGMP-dependent 3',5'-cyclic phosphodiesterase, and cGMP-specific 3',5'-cyclic phosphodiesterase, Uniprot O00408, O76074, P27815, P54750, Q01064, Q07343, Q08493, Q08499, Q13370, Q14123, and Q14432

Keywords

Phosphodiesterase 1, Phosphodiesterase 3, Phosphodiesterase 4, cGMP-dependent 3',5'-cyclic phosphodiesterase, and cGMP-specific 3',5'-cyclic phosphodiesterase, Tanabe Seiyaku Company, Ltd., Affinity

13 Research products, page 1 of 2

BindingDB Entry 50029923: TBA
2010IsAmongTopNSimilarDocuments
BindingDB Entry 50028591: The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.
2010IsAmongTopNSimilarDocuments
BindingDB Entry 50031179: Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5).
2010IsAmongTopNSimilarDocuments
BindingDB Entry 50008249: Aryl sulfonamides as selective PDE4 inhibitors.
2009IsAmongTopNSimilarDocuments
BindingDB Entry 50008644: 1-Arylnaphthalene lignan: a novel scaffold for type 5 phosphodiesterase inhibitor.
2009IsAmongTopNSimilarDocuments
BindingDB Entry 50016551: Discovery of hydroxamic acid analogs as dual inhibitors of phosphodiesterase-1 and -5.
2009IsAmongTopNSimilarDocuments
BindingDB Entry 50013694: Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
2022IsAmongTopNSimilarDocuments
BindingDB Entry 50034110: Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent region.
2012IsAmongTopNSimilarDocuments
Novel, Potent, and Selective Phosphodiesterase-4 Inhibitors as Antiasthmatic Agents: Synthesis and Biological Activities of a Series of 1-Pyridylnaphthalene Derivatives
1999IsDerivedFrom
BindingDB Entry 50035254: Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor.
2012IsAmongTopNSimilarDocuments

chevron_left
1
2
chevron_right

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average